Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: A retrospective chart review
- 30 April 2008
- journal article
- clinical trial
- Published by Elsevier BV in Schizophrenia Research
- Vol. 101 (1-3), 295-303
- https://doi.org/10.1016/j.schres.2008.01.028
Abstract
No abstract availableKeywords
This publication has 60 references indexed in Scilit:
- Metabolic syndrome and insulin resistance in schizophrenia patients receiving antipsychotics genotyped for the methylenetetrahydrofolate reductase (MTHFR) 677C/T and 1298A/C variantsSchizophrenia Research, 2008
- The Obesity Epidemic in the United States Gender, Age, Socioeconomic, Racial/Ethnic, and Geographic Characteristics: A Systematic Review and Meta-Regression AnalysisEpidemiologic Reviews, 2007
- Metabolic syndrome in Thai schizophrenic patients: a naturalistic one-year follow-up studyBMC Psychiatry, 2007
- Prevalence of Overweight and Obesity in the United States, 1999-2004JAMA, 2006
- Schizophrenia and increased risks of cardiovascular diseaseAmerican Heart Journal, 2005
- Diagnosis and Management of the Metabolic SyndromeCirculation, 2005
- The Changing Face of Cardiovascular RiskJournal of the American College of Cardiology, 2005
- Metabolic syndrome and schizophreniaThe British Journal of Psychiatry, 2005
- Impaired Fasting Glucose Tolerance in First-Episode, Drug-Naive Patients With SchizophreniaAmerican Journal of Psychiatry, 2003
- Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)JAMA, 2001